Key Takeaways
- • Lumonus, a digital oncology platform spun out of GenesisCare and chaired by former Anchorage Capital Group boss Merrick Howes, has entered a joint venture with Memorial Sloan Kettering Cancer Center (MSK), a leading New York-based cancer treatment facility, to scale AI-driven oncology workflows.
- • The partnership will license and co-develop MSK's ECHO mathematical optimisation engine into the Lumonus platform, targeting treatment planning—one of the most technically demanding segments of cancer care automation.
- • Lumonus has raised A$25–A$28 million in Series B funding to support the scaling of its AI-powered oncology platform globally, with this MSK collaboration positioned as a key milestone for moving automation from research validation to routine clinical deployment.
- • The joint venture combines MSK's established optimisation technology with Lumonus' broader software platform designed to automate and orchestrate critical oncology workflows, improving clinical quality and operational efficiency across radiation oncology and treatment planning.
Summary
Lumonus, the Australian digital oncology platform spun out of cancer services provider GenesisCare, has formalised a strategic joint venture with Memorial Sloan Kettering Cancer Center (MSK) in New York to accelerate the deployment of AI-native clinical workflows in cancer treatment planning. The agreement represents a significant institutional validation for Lumonus and marks a transition from pilot-stage technology toward scaled, routine clinical adoption.
Under the joint venture structure, Lumonus will license and co-develop MSK's proprietary ECHO mathematical optimisation engine, integrating it into the broader Lumonus platform. This partnership targets one of oncology's most technically complex domains: automated treatment planning, where precision, speed, and consistency directly impact clinical outcomes. By combining MSK's established optimisation algorithms with Lumonus' orchestration infrastructure, the collaboration aims to standardise and automate workflows that have historically relied on manual planning and expert review.
Lumonus, chaired by Merrick Howes (former head of Anchorage Capital Group), has secured A$25–A$28 million in Series B funding to support global scaling efforts. The MSK partnership is positioned as the cornerstone of this expansion, with executives emphasizing the transition from "promising results to scaled, routine deployment" across cancer centres. The platform's AI-native design targets radiation oncology practices and treatment planning workflows, automating critical decision points while maintaining clinical oversight and quality standards.
This venture reflects broader institutional demand for validated AI solutions in healthcare delivery, particularly in oncology where treatment complexity and standardization challenges create both clinical and operational friction. The partnership structure leverages MSK's clinical credibility and algorithmic expertise alongside Lumonus' software architecture, positioning the joint venture to establish a reference standard for AI-assisted cancer care workflows across the sector.
Under the joint venture structure, Lumonus will license and co-develop MSK's proprietary ECHO mathematical optimisation engine, integrating it into the broader Lumonus platform. This partnership targets one of oncology's most technically complex domains: automated treatment planning, where precision, speed, and consistency directly impact clinical outcomes. By combining MSK's established optimisation algorithms with Lumonus' orchestration infrastructure, the collaboration aims to standardise and automate workflows that have historically relied on manual planning and expert review.
Lumonus, chaired by Merrick Howes (former head of Anchorage Capital Group), has secured A$25–A$28 million in Series B funding to support global scaling efforts. The MSK partnership is positioned as the cornerstone of this expansion, with executives emphasizing the transition from "promising results to scaled, routine deployment" across cancer centres. The platform's AI-native design targets radiation oncology practices and treatment planning workflows, automating critical decision points while maintaining clinical oversight and quality standards.
This venture reflects broader institutional demand for validated AI solutions in healthcare delivery, particularly in oncology where treatment complexity and standardization challenges create both clinical and operational friction. The partnership structure leverages MSK's clinical credibility and algorithmic expertise alongside Lumonus' software architecture, positioning the joint venture to establish a reference standard for AI-assisted cancer care workflows across the sector.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.